calicivirus
nonenvelop
small
positivestrand
rna
virus
divid
five
genera
noroviru
lagoviru
sapoviru
vesiviru
neboviru
absenc
anim
cell
model
calicivirus
restrict
understand
biolog
particular
infect
human
norovirus
hunov
caus
viral
epidem
gastroenter
global
peopl
age
felin
caliciviru
fcv
murin
noroviru
use
wide
model
system
contribut
understand
hunov
fcv
belong
genu
vesiviru
highli
contagi
pathogen
wide
distribut
felin
popul
previou
fcv
isol
mainli
induc
upper
respiratori
tract
diseas
oral
ulcer
low
mortal
rate
howev
sever
outbreak
high
mortal
report
recent
year
gene
encod
capsid
protein
fcv
contain
variabl
region
evolutionari
rate
region
rang
substitutionsnucleotideyear
fcv
highest
evolutionari
rate
among
virus
although
one
serotyp
fcv
variabl
main
antigen
often
contribut
lack
efficaci
vaccin
widespread
vaccin
prevent
spread
fcv
natur
infect
cat
recov
fulli
fcv
infect
protect
infect
fcv
strain
addit
fcv
variant
inhibit
evad
host
immun
respons
persist
cat
recoveri
fcv
infect
clinic
symptom
disappear
mani
cat
continu
shed
viru
day
even
sever
year
previou
studi
found
fcv
strain
induc
express
vitro
may
key
factor
surviv
fcv
cat
failur
effici
control
fcv
infect
lead
high
preval
fcv
fcv
vaccin
reduc
durat
sever
clinic
sign
inhibit
viru
shed
infect
sinc
fcv
vaccin
provid
complet
protect
urgent
develop
effect
safe
antivir
drug
monotherapi
combin
treatment
product
type
interferon
ifn
involv
antivir
respons
broadspectrum
antivir
activ
trigger
presenc
viral
dsrna
byproduct
viral
replic
howev
mani
virus
evolv
multipl
strategi
evad
inhibit
ifn
respons
vitro
infect
fcv
strain
result
activ
promot
thu
allow
virus
evad
ifn
respons
sever
treatment
strategi
fcv
diseas
report
phosphorodiamid
morpholino
oligom
pmo
function
effici
drug
control
fcv
diseas
test
natur
outbreak
fcv
mefloquin
humanapprov
pharmaceut
compound
demonstr
effect
treatment
fcv
infect
combin
treatment
mefloquin
recombin
felin
interferon
result
higher
effici
control
fcv
infect
howev
unfavor
aspect
mani
drug
metabol
pathway
might
restrict
applic
lithium
chlorid
licl
wide
appli
import
therapeut
agent
nervou
system
disord
includ
alzheim
diseas
serou
ovarian
cancer
diabet
sever
studi
suggest
licl
act
antivir
agent
inhibit
growth
virus
coronaviru
herp
simplex
viru
type
porcin
reproduct
respiratori
syndrom
viru
prrsv
infecti
bronchiti
viru
moreov
licl
suppress
host
inflammatori
respons
regul
cell
apoptosi
restor
synthesi
host
protein
virusinfect
cell
previou
studi
found
licl
effici
suppress
fcv
replic
vitro
howev
antivir
therapi
singl
drug
often
caus
emerg
drugresist
fcv
strain
addit
high
evolutionari
rate
fcv
make
necessari
identifi
antivir
drug
germacron
one
main
constitu
volatil
oil
rhizoma
curcuma
suppress
angiogenesi
metastasi
contribut
restrict
cell
prolifer
due
potenti
inhibit
growth
tumour
cell
germacron
wide
use
anticanc
drug
china
demonstr
germacron
inhibit
replic
influenza
viru
vitro
impair
attachmententri
step
earli
event
viral
life
cycl
anoth
studi
also
found
germacron
may
potenti
drug
porcin
parvoviru
ppv
infect
current
studi
antivir
effect
germacron
fcv
replic
investig
measur
chang
viral
rna
vrna
level
viru
yield
result
indic
germacron
act
effici
antivir
drug
fcv
replic
fcv
strain
bolin
obtain
atcc
strain
hrbss
isol
ill
household
cat
describ
previous
crandellrees
felin
kidney
crfk
cell
atcc
cultur
dmem
hyclon
supplement
fetal
bovin
serum
gibco
penicillinstreptomycin
viru
stock
propag
crfk
cell
centrifug
g
min
kept
use
germacron
ca
purchas
belloncam
china
initi
dissolv
dimethyl
sulfoxid
dmso
sigmaaldrich
concentr
mm
dmso
vv
amount
dmso
constantli
maintain
sampl
dmso
concentr
vv
wide
use
poorli
solubl
polar
nonpolar
molecul
toxic
retin
neuron
cell
line
crfk
cell
plate
cellswel
prepar
prior
assay
next
day
cultur
medium
discard
germacron
ad
differ
concentr
dilut
serumfre
dmem
cell
treat
dmso
use
control
treatment
h
cytotox
assay
done
use
cell
count
donjindo
japan
accord
manufactur
protocol
wash
two
time
pb
dmem
solut
ad
cell
plate
incub
two
hour
optic
densiti
od
determin
use
multimod
plate
reader
pe
usa
excit
filter
rel
cell
viabil
calcul
percentag
mocktreat
control
cell
germacron
concentr
cytostat
concentr
consid
nontox
determin
antivir
efficaci
germacron
fcv
prolifer
cell
treat
one
hour
germacron
concentr
incub
cell
infect
strain
multipl
infect
moi
presenc
germacron
one
hour
wash
three
time
pb
cell
expos
germacron
twelv
hour
time
drug
exposur
test
one
hour
infect
test
endpoint
allow
step
viral
life
cycl
drug
act
determin
viru
yield
cell
supernat
measur
total
rna
isol
cell
level
vrna
determin
realtim
rtpcr
cell
seed
cultur
h
nontox
concentr
germacron
dmso
alon
mock
treatment
mix
viru
suspens
incub
one
hour
mixtur
contain
drug
viru
ad
cell
follow
incub
one
hour
moi
assay
level
vrna
cell
determin
realtim
rtpcr
cell
plate
inocul
strain
moi
dilut
differ
concentr
germacron
dmso
mock
treatment
one
hour
plate
incub
one
hour
level
vrna
determin
realtim
rtpcr
investig
antivir
efficaci
germacron
cell
inocul
strain
moi
one
hour
cell
wash
three
time
pb
infect
cell
expos
germacron
concentr
subject
mock
treatment
dmso
twelv
hour
recov
viru
yield
cell
supernat
determin
level
vrna
determin
realtim
rtpcr
determin
stage
viral
life
cycl
affect
drug
effect
simultan
treatment
pretreat
posttreat
evalu
cell
seed
plate
cultur
hour
cell
pretreat
germacron
concentr
one
hour
incub
cell
challeng
strain
moi
cell
simultan
expos
strain
moi
germacron
twelv
hour
cell
inocul
strain
moi
one
hour
prior
exposur
germacron
hpi
recov
viru
yield
cell
supernat
determin
hpi
level
vrna
measur
realtim
rtpcr
cell
treat
germacron
one
hour
prior
challeng
strain
bolin
hrbss
moi
time
drug
exposur
one
hour
challeng
end
experi
recov
viru
yield
cell
supernat
determin
hpi
protocol
viru
titrat
describ
previous
briefli
viru
stock
dilut
freeserum
dmem
appli
cell
onehour
adsorpt
period
medium
contain
fb
ad
h
postinocul
cytopath
effect
observ
follow
protocol
reed
viral
yield
calcul
median
tissu
cultur
infect
dose
protocol
realtim
rtpcr
describ
previous
total
rna
drugtreat
untreat
cell
isol
use
mini
kit
qiagen
accord
manufactur
instruct
transcript
rna
cdna
perform
use
primescript
strand
cdna
kit
takara
japan
follow
primer
fcv
propol
gapdh
design
fcvfor
fcvrev
gapdhfor
gapdhrev
procedur
pcr
consist
initi
step
min
follow
cycl
rel
level
rna
express
determin
method
gapdh
mrna
analyz
load
control
wash
three
time
pb
cell
fix
paraformaldehyd
min
room
temperatur
permeabil
triton
min
cell
wash
three
time
felin
antifcv
serum
dilut
pb
incub
cell
room
temperatur
one
hour
cell
incub
fitcconjug
goat
anticat
igg
dilut
pb
jackson
usa
cell
wash
three
time
incub
dapi
dilut
pb
room
temperatur
min
fluoresc
examin
use
invert
fluoresc
microscop
olympu
experi
perform
triplic
data
present
mean
sd
signific
differ
analyz
oneway
anova
unpair
ttest
use
graphpad
prism
softwar
comparison
drug
mocktreat
group
pvalu
consid
statist
signific
indic
follow
p
cytotox
assay
show
rel
cell
viabil
greater
exposur
germacron
concentr
rang
h
wherea
viabil
less
treatment
germacron
h
fig
treatment
germacron
valu
result
signific
differ
cell
morpholog
data
shown
compar
mocktreat
cell
concentr
rang
therefor
select
antivir
assay
evalu
whether
germacron
could
inhibit
fcv
prolifer
cell
treat
differ
concentr
germacron
one
hour
prior
infect
strain
presenc
drug
result
show
germacron
treatment
led
signific
reduct
vrna
level
compar
mock
treatment
inhibitori
effect
dosedepend
fig
treatment
germacron
affect
viru
yield
significantli
treatment
germacron
inhibit
viral
prolifer
least
tenfold
fig
ifa
experi
strong
signal
observ
mocktreat
cell
well
cell
treat
germacron
hpi
fluoresc
signal
decreas
treatment
germacron
fig
fluoresc
signal
observ
cell
control
group
result
indic
pretreat
germacron
result
signific
reduct
viru
titer
vrna
level
concentrationdepend
manner
investig
whether
antivir
effect
germacron
associ
reduct
viru
attach
entri
cell
germacron
mix
viru
suspens
one
hour
ad
cell
plate
incub
one
hour
amount
vrna
measur
differ
found
drugtreat
mocktreat
sampl
fig
suggest
germacron
treatment
affect
viral
attach
cell
investig
whether
germacron
treatment
inhibit
fcv
entri
cell
cell
inocul
viru
one
hour
cell
expos
germacron
one
hour
level
vrna
determin
quantit
pcr
vrna
level
decreas
germacronetr
cell
fig
indic
drug
affect
virion
entri
sinc
germacron
treatment
affect
fcv
attach
entri
specul
germacron
might
affect
viral
prolifer
cell
infect
viru
one
hour
treat
germacron
concentr
twelv
hour
level
vrna
recov
viru
yield
determin
compar
mocktreat
cell
germacron
treatment
led
decreas
respect
rel
vrna
level
fig
moreov
viru
load
cell
treat
germacron
decreas
fig
experi
perform
analyz
inhibitori
effect
germacron
viral
prolifer
cell
expos
germacron
prior
viru
challeng
shown
fig
reduct
amount
vrna
detect
hpi
observ
h
h
germacronetr
group
compar
mocktreat
cell
viru
load
significantli
reduc
cell
treat
germacron
h
h
h
signific
reduct
detect
h
h
fig
thu
germacron
treatment
chiefli
affect
earli
stage
viral
prolifer
antivir
assay
perform
evalu
whether
germacron
affect
replic
refer
strain
field
isol
follow
treatment
germacron
mock
treatment
cell
infect
differ
fcv
isol
one
hour
treat
germacron
twelv
hour
recov
viru
yield
determin
hpi
shown
fig
germacron
treatment
significantli
suppress
growth
refer
strain
bolin
field
isol
hrbss
germacron
treatment
nearli
tenfold
decreas
viru
yield
detect
refer
strain
field
isol
compar
mock
treatment
fig
famili
calicivirida
highli
divers
famili
human
nonhuman
pathogen
virus
human
pathogen
noroviru
major
caus
viral
gastroenter
worldwid
human
pathogen
noroviru
suitabl
vitro
cultur
system
restrict
vaccin
develop
antivir
drug
may
better
method
control
human
noroviru
infect
felin
caliciviru
fcv
use
wide
model
system
acceler
learn
hunov
develop
antivir
drug
fcv
may
help
control
human
noroviru
infect
rhizoma
curcuma
appli
treatment
tumor
inflamm
tradit
chines
medicin
germacron
key
compon
essenti
oil
isol
rhizoma
curcuma
use
antituss
antiinflammatori
antidepress
antifeed
antifung
antibacteri
antitumor
propos
recent
germacron
shown
inhibit
influenza
viru
replic
concentrationdepend
manner
ppv
caus
reproduct
failur
sow
antivir
drug
may
altern
method
protect
anim
ppv
infect
chen
et
al
report
preexposur
germacron
significantli
inhibit
ppv
replic
earli
stage
concentrationdepend
manner
studi
show
germacron
suppress
fcv
replic
well
product
vrna
progeni
viru
antivir
effect
germacron
treatment
occur
chiefli
earli
stage
viru
replic
concentrationdepend
manner
data
suggest
germacron
might
potenti
drug
treatment
fcv
diseas
investig
requir
examin
antivir
effect
safeti
vivo
studi
far
focus
vitro
data
vivo
data
urgent
need
explor
safeti
issu
sinc
germacron
affect
fcv
ppv
attach
entri
inocul
prior
infect
result
highest
inhibitori
effici
case
influenza
viru
specul
treatment
germacron
may
affect
express
host
gene
may
requir
viral
replic
infer
germacron
may
protect
infect
fcv
strain
although
fcv
evolv
quickli
due
low
fidel
rnadepend
rna
polymeras
one
serotyp
identifi
far
anoth
report
also
demonstr
strain
seven
strain
similar
sensit
mefloquin
treatment
moreov
strain
use
studi
includ
current
circul
virus
china
show
similar
sensit
germacron
treatment
result
suggest
germacron
use
effect
broadspectrum
antifcv
drug
either
alon
combin
antifcv
compound
treatment
cat
addit
use
combin
germacron
exist
antivir
drug
might
help
prevent
develop
resist
drug
develop
fcv
futur
studi
germacron
identifi
potent
inhibitor
fcv
replic
present
low
concentr
germacron
treatment
chiefli
affect
earli
phase
viral
replic
moreov
evalu
inhibitori
effect
caliciviru
extend
broad
spectrum
antivir
effect
investig
need
optim
drug
clinic
applic
treatment
fcv
also
necessari
analyz
effect
germacron
felin
virus
